Skip to content
CompoundSci
All peptides
Research vial labelled Oxytocin, a Cognitive peptide studied in preclinical and clinical literature

Oxytocin

The file here is mostly preclinical work plus clinic and community practice, not registrational trials.

The intranasal social-behaviour literature has a serious replication problem. Read the meta-analyses, not the single studies.

General profile

Class
Cognitive
Evidence
Mixed or moderate evidence
Studied dose range
10–40 IU intranasal in most trials
Frequency in protocols
As studied, intermittent
Route
Intranasal in the social-cognition literature
Half life
~3 minutes
Reconstitution
Supplied as a solution in most research settings
Storage
Refrigerated

Timing and cycling in the literature

Usually dosed in the evening window

Intermittent, per study design

A three minute half-life means effects are acute and short. Trials dose it immediately before the situation being measured.

Reported cycle: 4 weeks on, 4 weeks off

Trial use is acute and situational rather than a standing course.

Watch for: Mood changes, and be aware the social-cognition literature has a serious replication problem.

What it conflicts with

Three separate questions, kept separate. A hard stop means the mechanisms must not run together at all and timing does not fix it. A syringe rule means the same day is fine but one barrel is not. Redundancy is not dangerous, it is paying twice to hit one target.

  • Separate syringesSame day fine, same syringe not

    Oxytocin + PT-141

    Not at full doses together

    Both flush hard. Combined full doses stack redness, nausea and vomiting rather than adding any benefit.

Most syringe compatibility claims here are practice and expert consensus, not peer reviewed mixing studies. A clear liquid after mixing does not prove the compounds are still active, and cloudiness, particles or gelling means discard. Active cancer, pregnancy, major cardiac care and heavy immunosuppression override every stack preference on this page.

See how Oxytocin fits your week

The injection scheduler spaces doses using the clinical timing data, flags the pairs above before you draw them, and tells you why.

Model this in the injection scheduler

The studies

Human trials: No completed human efficacy trial that establishes a dose for the use people are chasing.

Open questions: Treat published dosing as observed practice, not a validated protocol.

Published papers

Indexed from Europe PMC and refreshed weekly. Each link opens the paper itself.

Search the full literature